”a phase 3 company priced like a phase 2 company”.
that’s because it is a phase 2 company.
this asset had negligible data in the old phase 2 it’s almost pointless. So the part 1 of this current trial first 70 patients that takes it to the mid Mar futility analysis is effectively the phase 2 that was never done for this asset.
Ann: Quarterly Appendix 4C and Activities Report, page-37
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
60.5¢ |
Change
0.050(9.01%) |
Mkt cap ! $317.4M | |||
| Open | High | Low | Value | Volume |
| 57.0¢ | 61.3¢ | 56.5¢ | $1.569M | 2.699M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15700 | 60.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.5¢ | 18253 | 2 |
View Market Depth
| Last trade - 15.30pm 20/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |